Carol L. Prives - Publications

Biological Sciences Columbia University, New York, NY 
p53 tumour suppressor protein

219 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2021 Klein AM, Biderman L, Tong D, Alaghebandan B, Plumber SA, Mueller HS, van Vlimmeren A, Katz C, Prives C. MDM2, MDMX, and p73 regulate cell-cycle progression in the absence of wild-type p53. Proceedings of the National Academy of Sciences of the United States of America. 118. PMID 34716260 DOI: 10.1073/pnas.2102420118  0.872
2021 Ellison V, Annor GK, Freedman C, Xiao G, Lundine D, Freulich E, Prives C, Bargonetti J. Frame-shift mediated reduction of gain-of-function p53 R273H and deletion of the R273H C-terminus in breast cancer cells result in replication-stress sensitivity. Oncotarget. 12: 1128-1146. PMID 34136083 DOI: 10.18632/oncotarget.27975  0.412
2021 Tong DR, Zhou W, Katz C, Regunath K, Venkatesh D, Ihuegbu C, Manfredi JJ, Laptenko O, Prives C. p53 frameshift mutations couple loss-of-function with unique neomorphic activities. Molecular Cancer Research : McR. PMID 34045312 DOI: 10.1158/1541-7786.MCR-20-0691  0.501
2021 Klein AM, de Queiroz RM, Venkatesh D, Prives C. The roles and regulation of MDM2 and MDMX: it is not just about p53. Genes & Development. 35: 575-601. PMID 33888565 DOI: 10.1101/gad.347872.120  0.5
2020 Venkatesh D, Stockwell BR, Prives C. p21 can be a barrier to ferroptosis independent of p53. Aging. 12: 17800-17814. PMID 32979260 DOI: 10.18632/aging.103961  0.493
2020 Venkatesh D, O'Brien NA, Zandkarimi F, Tong DR, Stokes ME, Dunn DE, Kengmana ES, Aron AT, Klein AM, Csuka JM, Moon SH, Conrad M, Chang CJ, Lo DC, D'Alessandro A, ... Prives C, et al. MDM2 and MDMX promote ferroptosis by PPARα-mediated lipid remodeling. Genes & Development. PMID 32079652 DOI: 10.1101/Gad.334219.119  0.536
2020 Nikolaev A, Tong D, Xing C, Zeng L, Prives C, Bonner J, Yang E. Pharmacological Targeting Of Mutant p53 Gain-of-Function Represses Mevalonate Pathway Of Cholesterol Biosynthesis And Sensitizes Tumor Cells To Radiation International Journal of Radiation Oncology*Biology*Physics. 108: e562. DOI: 10.1016/j.ijrobp.2020.07.1739  0.319
2019 Bargonetti J, Prives C. Gain-of-function mutant p53: history and speculation. Journal of Molecular Cell Biology. 11: 605-609. PMID 31283823 DOI: 10.1093/Jmcb/Mjz067  0.465
2018 Moon SH, Huang CH, Houlihan SL, Regunath K, Freed-Pastor WA, Morris JP, Tschaharganeh DF, Kastenhuber ER, Barsotti AM, Culp-Hill R, Xue W, Ho YJ, Baslan T, Li X, Mayle A, ... ... Prives C, et al. p53 Represses the Mevalonate Pathway to Mediate Tumor Suppression. Cell. PMID 30580964 DOI: 10.1016/J.Cell.2018.11.011  0.853
2018 Muniz de Queiroz R, Prives C. Unfolding the roles of resveratrol in p53 regulation. Oncotarget. 9: 34455-34456. PMID 30349639 DOI: 10.18632/Oncotarget.26185  0.559
2018 Fomin V, Richard P, Hoque M, Li C, Gu Z, Fissore-O'Leary M, Tian B, Prives C, Manley JL. The gene, implicated in ALS/FTD, encodes a protein that functions in control of endothelin and glutamate signaling. Molecular and Cellular Biology. PMID 30150298 DOI: 10.1128/Mcb.00155-18  0.314
2018 Karni-Schmidt O, Friedler A, Zupnick A, McKinney K, Mattia M, Beckerman R, Bouvet P, Sheetz M, Fersht A, Prives C. Correction: Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus. Oncogene. 37: 4901-4902. PMID 30068941 DOI: 10.1038/s41388-018-0321-1  0.794
2018 Rokudai S, Li Y, Otaka Y, Fujieda M, Owens DM, Christiano AM, Nishiyama M, Prives C. STXBP4 regulates APC/C-mediated p63 turnover and drives squamous cell carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America. PMID 29735662 DOI: 10.1073/Pnas.1718546115  0.507
2018 Rastogi C, Rube HT, Kribelbauer JF, Crocker J, Loker RE, Martini GD, Laptenko O, Freed-Pastor WA, Prives C, Stern DL, Mann RS, Bussemaker HJ. Accurate and sensitive quantification of protein-DNA binding affinity. Proceedings of the National Academy of Sciences of the United States of America. PMID 29610332 DOI: 10.1073/Pnas.1714376115  0.792
2018 Katz C, Low-Calle AM, Choe J, Laptenko O, Tong D, Joseph-Chowdhury JN, Garofalo F, Zhu Y, Friedler A, Prives C. Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers. Genes & Development. PMID 29549180 DOI: 10.1101/Gad.304071.117  0.641
2018 Wu D, Prives C. Relevance of the p53-MDM2 axis to aging. Cell Death & Differentiation. 25: 169-179. PMID 29192902 DOI: 10.1038/Cdd.2017.187  0.497
2017 Lessel D, Wu D, Trujillo C, Ramezani T, Lessel I, Alwasiyah MK, Saha B, Hisama FM, Rading K, Goebel I, Schütz P, Speit G, Högel J, Thiele H, Nürnberg G, ... ... Prives C, et al. Dysfunction of the MDM2/p53 axis is linked to premature aging. The Journal of Clinical Investigation. PMID 28846075 DOI: 10.1172/Jci92171  0.562
2017 Laptenko O, Prives C. p53: master of life, death, and the epigenome. Genes & Development. 31: 955-956. PMID 28637690 DOI: 10.1101/Gad.302364.117  0.509
2017 Kribelbauer JF, Laptenko O, Chen S, Martini GD, Freed-Pastor WA, Prives C, Mann RS, Bussemaker HJ. Quantitative Analysis of the DNA Methylation Sensitivity of Transcription Factor Complexes. Cell Reports. 19: 2383-2395. PMID 28614722 DOI: 10.1016/J.Celrep.2017.05.069  0.814
2017 Otaka Y, Rokudai S, Kaira K, Fujieda M, Horikoshi I, Iwakawa-Kawabata R, Yoshiyama S, Yokobori T, Ohtaki Y, Shimizu K, Oyama T, Tamura J, Prives C, Nishiyama M. STXBP4 Drives Tumor Growth and Is Associated with Poor Prognosis through PDGF Receptor Signaling in Lung Squamous Cell Carcinoma. Clinical Cancer Research. 23: 3442-3452. PMID 28087642 DOI: 10.1158/1078-0432.Ccr-16-1815  0.33
2017 Pfister NT, Prives C. Transcriptional Regulation by Wild-Type and Cancer-Related Mutant Forms of p53. Cold Spring Harbor Perspectives in Medicine. 7. PMID 27836911 DOI: 10.1101/Cshperspect.A026054  0.543
2017 Freed-Pastor W, Prives C. Targeting mutant p53 through the mevalonate pathway. Nature Cell Biology. 18: 1122-1124. PMID 27784901 DOI: 10.1038/Ncb3435  0.847
2016 Yoh KE, Regunath K, Guzman A, Lee SM, Pfister NT, Akanni O, Kaufman LJ, Prives C, Prywes R. Repression of p63 and induction of EMT by mutant Ras in mammary epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. PMID 27681615 DOI: 10.1073/Pnas.1613417113  0.44
2016 Laptenko O, Tong DR, Manfredi J, Prives C. The Tail That Wags the Dog: How the Disordered C-Terminal Domain Controls the Transcriptional Activities of the p53 Tumor-Suppressor Protein. Trends in Biochemical Sciences. PMID 27669647 DOI: 10.1016/J.Tibs.2016.08.011  0.583
2016 Beckerman R, Yoh K, Mattia-Sansobrino M, Zupnick A, Laptenko O, Karni-Schmidt O, Ahn J, Byeon IJ, Keezer S, Prives C. Lysines in the tetramerization domain of p53 selectively modulate G1 arrest. Cell Cycle (Georgetown, Tex.). 1-14. PMID 27210019 DOI: 10.1080/15384101.2016.1170270  0.865
2016 Pfister NT, Prives C. Chromatin dysregulation by mutant p53 Oncotarget. 7: 29875-29876. PMID 27127877 DOI: 10.18632/Oncotarget.7922  0.618
2016 Karni-Schmidt O, Lokshin M, Prives C. The Roles of MDM2 and MDMX in Cancer. Annual Review of Pathology. PMID 27022975 DOI: 10.1146/Annurev-Pathol-012414-040349  0.82
2015 Prives C, Lowe SW. Cancer: Mutant p53 and chromatin regulation. Nature. 525: 199-200. PMID 26331537 DOI: 10.1038/Nature15212  0.56
2015 Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J, Hoque M, Tian B, Gunaratne J, Engebraaten O, Manley JL, ... ... Prives C, et al. Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes & Development. 29: 1298-315. PMID 26080815 DOI: 10.1101/Gad.263202.115  0.843
2015 Laptenko O, Shiff I, Freed-Pastor W, Zupnick A, Mattia M, Freulich E, Shamir I, Kadouri N, Kahan T, Manfredi J, Simon I, Prives C. The p53 C terminus controls site-specific DNA binding and promotes structural changes within the central DNA binding domain. Molecular Cell. 57: 1034-46. PMID 25794615 DOI: 10.1016/J.Molcel.2015.02.015  0.826
2015 Otaka Y, Rokudai S, Kaira K, Shimizu K, Ito M, Ichihara A, Kawabata R, Yoshiyama S, Yamane A, Asao T, Prives C, Nishiyama M. Abstract 2070: Stxbp4 suppresses APC/C mediated turnover of p63 and increases tumorigenicity and malignancy Cancer Research. 75: 2070-2070. DOI: 10.1158/1538-7445.Am2015-2070  0.496
2015 Prives C. p53 with a Human Touch Cell. 162: 463-464. DOI: 10.1016/J.Cell.2015.07.029  0.525
2014 Pfister NT, Yoh KE, Prives C. p53, DNA damage, and NAD+ homeostasis. Cell Cycle. 13: 1661-1662. PMID 24810733 DOI: 10.4161/Cc.29151  0.639
2014 Weissmueller S, Manchado E, Saborowski M, Morris JP, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T, Aust D, Markert EK, Wu J, Grimmond SM, Pilarsky C, ... Prives C, et al. Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor β signaling. Cell. 157: 382-94. PMID 24725405 DOI: 10.1016/J.Cell.2014.01.066  0.52
2014 Prives CL. Abstract PL01-02: The two faces of p53: Tumor suppressor and oncogene Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Pl01-02  0.61
2014 Poyurovsky MV, Prives C. P53: Guardian of the metabolome P53 in the Clinics. 47-64. DOI: 10.1007/978-1-4614-3676-8_3  0.727
2013 Zhu Y, Regunath K, Jacq X, Prives C. Cisplatin causes cell death via TAB1 regulation of p53/MDM2/MDMX circuitry Genes & Development. 27: 1739-1751. PMID 23934659 DOI: 10.1101/Gad.212258.112  0.56
2013 Daftuar L, Zhu Y, Jacq X, Prives C. Ribosomal proteins RPL37, RPS15 and RPS20 regulate the Mdm2-p53-MdmX network. Plos One. 8: e68667. PMID 23874713 DOI: 10.1371/Journal.Pone.0068667  0.633
2013 Mansilla SF, Soria G, Vallerga MB, Habif M, Martínez-López W, Prives C, Gottifredi V. UV-triggered p21 degradation facilitates damaged-DNA replication and preserves genomic stability. Nucleic Acids Research. 41: 6942-51. PMID 23723248 DOI: 10.1093/nar/gkt475  0.475
2013 Laptenko O, Prives C. Anything but Simple: A Phosphorylation-Driven Toggle within Brd4 Triggers Gene-Specific Transcriptional Activation Molecular Cell. 49: 838-839. PMID 23473602 DOI: 10.1016/J.Molcel.2013.02.021  0.302
2013 Rokudai S, Laptenko O, Arnal SM, Taya Y, Kitabayashi I, Prives C. MOZ increases p53 acetylation and premature senescence through its complex formation with PML Proceedings of the National Academy of Sciences of the United States of America. 110: 3895-3900. PMID 23431171 DOI: 10.1073/Pnas.1300490110  0.607
2013 Moon S, Prives CL. Mutant p53 succumbs to starvation. Cell Cycle. 12: 867-867. PMID 23421997 DOI: 10.4161/Cc.23911  0.606
2012 Bursać S, Brdovčak MC, Pfannkuchen M, Orsolić I, Golomb L, Zhu Y, Katz C, Daftuar L, Grabušić K, Vukelić I, Filić V, Oren M, Prives C, Volarevic S. Mutual protection of ribosomal proteins L5 and L11 from degradation is essential for p53 activation upon ribosomal biogenesis stress. Proceedings of the National Academy of Sciences of the United States of America. 109: 20467-72. PMID 23169665 DOI: 10.1073/Pnas.1218535109  0.37
2012 Biderman L, Manley JL, Prives C. Mdm2 and MdmX as Regulators of Gene Expression. Genes & Cancer. 3: 264-73. PMID 23150759 DOI: 10.1177/1947601912455331  0.85
2012 Singer S, Zhao R, Barsotti AM, Ouwehand A, Fazollahi M, Coutavas E, Breuhahn K, Neumann O, Longerich T, Pusterla T, Powers MA, Giles KM, Leedman PJ, Hess J, Grunwald D, ... ... Prives C, et al. Nuclear pore component Nup98 is a potential tumor suppressor and regulates posttranscriptional expression of select p53 target genes. Molecular Cell. 48: 799-810. PMID 23102701 DOI: 10.1016/J.Molcel.2012.09.020  0.849
2012 Laptenko O, Prives C. The p53-HAT connection: PCAF rules? Cell Cycle. 11: 2975-2975. PMID 22889733 DOI: 10.4161/Cc.21528  0.63
2012 Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes & Development. 26: 1268-86. PMID 22713868 DOI: 10.1101/Gad.190678.112  0.85
2012 Biderman L, Poyurovsky MV, Assia Y, Manley JL, Prives C. MdmX is required for p53 interaction with and full induction of the Mdm2 promoter after cellular stress. Molecular and Cellular Biology. 32: 1214-25. PMID 22290440 DOI: 10.1128/Mcb.06150-11  0.881
2012 Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li W, Polotskaia A, Bissell MJ, Osborne TF, Tian B, Lowe SW, Silva JM, ... ... Prives C, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell. 148: 244-58. PMID 22265415 DOI: 10.1016/J.Cell.2011.12.017  0.837
2012 Barsotti AM, Beckerman R, Laptenko O, Huppi K, Caplen NJ, Prives C. p53-Dependent induction of PVT1 and miR-1204. The Journal of Biological Chemistry. 287: 2509-19. PMID 22110125 DOI: 10.1074/Jbc.M111.322875  0.804
2012 Singer S, Barsotti A, Fazollahi M, Ouwehand A, Grünwald D, Breuhahn K, Bussemaker H, Singer R, Schirmacher P, Prives C. A nuclear pore component regulates select p53 target genes Zeitschrift FüR Gastroenterologie. 50. DOI: 10.1055/S-0031-1296009  0.331
2011 Herman AG, Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C, Stockwell BR. Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based ubiquitination assay. Cancer Discovery. 1: 312-25. PMID 22586610 DOI: 10.1158/2159-8290.Cd-11-0104  0.738
2011 Freed-Pastor WA, Prives C. Dissimilar DNA binding by p53 in normal and tumor-derived cells. Cell Cycle (Georgetown, Tex.). 10: 4207. PMID 22127203 DOI: 10.4161/Cc.10.24.18723  0.832
2011 Sasaki M, Kawahara K, Nishio M, Mimori K, Kogo R, Hamada K, Itoh B, Wang J, Komatsu Y, Yang YR, Hikasa H, Horie Y, Yamashita T, Kamijo T, Zhang Y, ... ... Prives C, et al. Regulation of the MDM2-P53 pathway and tumor growth by PICT1 via nucleolar RPL11. Nature Medicine. 17: 944-51. PMID 21804542 DOI: 10.1038/Nm.2392  0.573
2011 Huggins P, Zhong S, Shiff I, Beckerman R, Laptenko O, Prives C, Schulz MH, Simon I, Bar-Joseph Z. DECOD: fast and accurate discriminative DNA motif finding. Bioinformatics (Oxford, England). 27: 2361-7. PMID 21752801 DOI: 10.1093/Bioinformatics/Btr412  0.701
2011 Laptenko O, Beckerman R, Freulich E, Prives C. p53 binding to nucleosomes within the p21 promoter in vivo leads to nucleosome loss and transcriptional activation. Proceedings of the National Academy of Sciences of the United States of America. 108: 10385-90. PMID 21606339 DOI: 10.1073/Pnas.1105680108  0.86
2011 Karni-Schmidt O, Castillo-Martin M, Shen TH, HuaiShen T, Gladoun N, Domingo-Domenech J, Sanchez-Carbayo M, Li Y, Lowe S, Prives C, Cordon-Cardo C. Distinct expression profiles of p63 variants during urothelial development and bladder cancer progression. The American Journal of Pathology. 178: 1350-60. PMID 21356385 DOI: 10.1016/J.Ajpath.2010.11.061  0.831
2011 Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IL, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A, Prives C. Erratum: The C terminus of p53 binds the N-terminal domain of MDM2 Nature Structural & Molecular Biology. 18: 516-516. DOI: 10.1038/Nsmb0411-516C  0.777
2010 Daftuar L, Zhu Y, Prives C. Ribosomal protein L37 and the p53 network. Cell Cycle (Georgetown, Tex.). 9: 4259. PMID 21057197 DOI: 10.4161/Cc.9.21.13527  0.383
2010 Peart MJ, Poyurovsky MV, Kass EM, Urist M, Verschuren EW, Summers MK, Jackson PK, Prives C. APC/C(Cdc20) targets E2F1 for degradation in prometaphase. Cell Cycle (Georgetown, Tex.). 9: 3956-64. PMID 20948288 DOI: 10.4161/Cc.9.19.13162  0.813
2010 Barsotti AM, Prives C. Noncoding RNAs: the missing "linc" in p53-mediated repression. Cell. 142: 358-60. PMID 20691894 DOI: 10.1016/J.Cell.2010.07.029  0.825
2010 Beckerman R, Prives C. Transcriptional regulation by p53. Cold Spring Harbor Perspectives in Biology. 2: a000935. PMID 20679336 DOI: 10.1101/Cshperspect.A000935  0.836
2010 Priest C, Prives C, Poyurovsky MV. Deconstructing nucleotide binding activity of the Mdm2 RING domain Nucleic Acids Research. 38: 7587-7598. PMID 20671028 DOI: 10.1093/Nar/Gkq669  0.747
2010 Poyurovsky MV, Prives C. P53 and aging: A fresh look at an old paradigm. Aging. 2: 380-2. PMID 20657036 DOI: 10.18632/AGING.100179  0.639
2010 Poyurovsky MV, Katz C, Laptenko O, Beckerman R, Lokshin M, Ahn J, Byeon IJ, Gabizon R, Mattia M, Zupnick A, Brown LM, Friedler A, Prives C. The C terminus of p53 binds the N-terminal domain of MDM2. Nature Structural & Molecular Biology. 17: 982-9. PMID 20639885 DOI: 10.1038/Nsmb.1872  0.85
2010 Suzuki S, Tanaka T, Poyurovsky MV, Nagano H, Mayama T, Ohkubo S, Lokshin M, Hosokawa H, Nakayama T, Suzuki Y, Sugano S, Sato E, Nagao T, Yokote K, Tatsuno I, ... Prives C, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proceedings of the National Academy of Sciences of the United States of America. 107: 7461-6. PMID 20351271 DOI: 10.1073/Pnas.1002459107  0.813
2010 Prives C, Barsotti AM, Beckerman R, Biderman L, Laptenko O, Mattia M, Tanaka T, Singer S, Zupnick A. 636 Mechanisms by which the p53 tumour suppressor protein selects its target genes Ejc Supplements. 8: 161. DOI: 10.1016/S1359-6349(10)71436-1  0.819
2009 Zhu Y, Prives C. p53 and Metabolism: The GAMT Connection Molecular Cell. 36: 351-352. PMID 19917243 DOI: 10.1016/J.Molcel.2009.10.026  0.367
2009 Barsotti AM, Prives C. Pro-proliferative FoxM1 is a target of p53-mediated repression. Oncogene. 28: 4295-305. PMID 19749794 DOI: 10.1038/Onc.2009.282  0.875
2009 Harris CR, Dewan A, Zupnick A, Normart R, Gabriel A, Prives C, Levine AJ, Hoh J. p53 responsive elements in human retrotransposons. Oncogene. 28: 3857-65. PMID 19718052 DOI: 10.1038/Onc.2009.246  0.821
2009 Zhu Y, Poyurovsky MV, Li Y, Biderman L, Stahl J, Jacq X, Prives C. Ribosomal protein S7 is both a regulator and a substrate of MDM2. Molecular Cell. 35: 316-26. PMID 19683495 DOI: 10.1016/J.Molcel.2009.07.014  0.83
2009 Tsvetkov P, Reuven N, Prives C, Shaul Y. Susceptibility of p53 unstructured N terminus to 20 S proteasomal degradation programs the stress response. The Journal of Biological Chemistry. 284: 26234-42. PMID 19617345 DOI: 10.1074/Jbc.M109.040493  0.494
2009 Beckerman R, Donner AJ, Mattia M, Peart MJ, Manley JL, Espinosa JM, Prives C. A role for Chk1 in blocking transcriptional elongation of p21 RNA during the S-phase checkpoint. Genes & Development. 23: 1364-77. PMID 19487575 DOI: 10.1101/Gad.1795709  0.857
2009 Ahn J, Poyurovsky MV, Baptiste N, Beckerman R, Cain C, Mattia M, McKinney K, Zhou J, Zupnick A, Gottifredi V, Prives C. Dissection of the sequence-specific DNA binding and exonuclease activities reveals a superactive yet apoptotically impaired mutant p53 protein. Cell Cycle (Georgetown, Tex.). 8: 1603-15. PMID 19462533 DOI: 10.4161/Cc.8.10.8548  0.829
2009 Li Y, Peart MJ, Prives C. Stxbp4 Regulates ΔNp63 Stability by Suppression of RACK1-Dependent Degradation Molecular and Cellular Biology. 29: 3953-3963. PMID 19451233 DOI: 10.1128/Mcb.00449-09  0.53
2009 Vousden KH, Prives C. Blinded by the Light: The Growing Complexity of p53 Cell. 137: 413-431. PMID 19410540 DOI: 10.1016/J.Cell.2009.04.037  0.594
2009 Kass EM, Poyurovsky MV, Zhu Y, Prives C. Mdm2 and PCAF increase Chk2 ubiquitination and degradation independently of their intrinsic E3 ligase activities. Cell Cycle (Georgetown, Tex.). 8: 430-7. PMID 19176998 DOI: 10.4161/Cc.8.3.7624  0.813
2009 Li H, Okamoto K, Peart MJ, Prives C. Lysine-independent turnover of cyclin G1 can be stabilized by B'alpha subunits of protein phosphatase 2A. Molecular and Cellular Biology. 29: 919-928. PMID 18981217 DOI: 10.1128/Mcb.00907-08  0.386
2008 Prives C, Gottifredi V. The p21 and PCNA partnership: a new twist for an old plot. Cell Cycle. 7: 3840-3846. PMID 19066467 DOI: 10.4161/Cc.7.24.7243  0.53
2008 Karni-Schmidt O, Zupnick A, Castillo M, Ahmed A, Matos T, Bouvet P, Cordon-Cardo C, Prives C. p53 is localized to a sub-nucleolar compartment after proteasomal inhibition in an energy-dependent manner. Journal of Cell Science. 121: 4098-105. PMID 19033390 DOI: 10.1242/Jcs.030098  0.845
2008 Soria G, Speroni J, Podhajcer OL, Prives C, Gottifredi V. p21 differentially regulates DNA replication and DNA-repair-associated processes after UV irradiation. Journal of Cell Science. 121: 3271-82. PMID 18782865 DOI: 10.1242/Jcs.027730  0.632
2008 Prives C, White E. Does control of mutant p53 by Mdm2 complicate cancer therapy? Genes & Development. 22: 1259-64. PMID 18483214 DOI: 10.1101/Gad.1680508  0.579
2008 Baptiste-Okoh N, Barsotti AM, Prives C. Caspase 2 is both required for p53-mediated apoptosis and downregulated by p53 in a p21-dependent manner. Cell Cycle (Georgetown, Tex.). 7: 1133-8. PMID 18418048 DOI: 10.4161/Cc.7.9.5805  0.864
2008 Baptiste-Okoh N, Barsotti AM, Prives C. A role for caspase 2 and PIDD in the process of p53-mediated apoptosis. Proceedings of the National Academy of Sciences of the United States of America. 105: 1937-42. PMID 18238895 DOI: 10.1073/Pnas.0711800105  0.848
2007 Tanaka T, Ohkubo S, Tatsuno I, Prives C. hCAS/CSE1L Associates with Chromatin and Regulates Expression of Select p53 Target Genes Cell. 130: 638-650. PMID 17719542 DOI: 10.1016/J.Cell.2007.08.001  0.559
2007 Kass EM, Ahn J, Tanaka T, Freed-Pastor WA, Keezer S, Prives C. Stability of checkpoint kinase 2 is regulated via phosphorylation at serine 456. The Journal of Biological Chemistry. 282: 30311-21. PMID 17715138 DOI: 10.1074/Jbc.M704642200  0.792
2007 Li Y, Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function Oncogene. 26: 2220-2225. PMID 17401431 DOI: 10.1038/Sj.Onc.1210311  0.6
2007 Karni-Schmidt O, Friedler A, Zupnick A, McKinney K, Mattia M, Beckerman R, Bouvet P, Sheetz M, Fersht A, Prives C. Energy-dependent nucleolar localization of p53 in vitro requires two discrete regions within the p53 carboxyl terminus. Oncogene. 26: 3878-91. PMID 17237827 DOI: 10.1038/Sj.Onc.1210162  0.838
2007 Poyurovsky MV, Priest C, Kentsis A, Borden KLB, Pan ZQ, Pavletich N, Prives C. The Mdm2 RING domain C-terminus is required for supramolecular assembly and ubiquitin ligase activity Embo Journal. 26: 90-101. PMID 17170710 DOI: 10.1038/Sj.Emboj.7601465  0.726
2007 Lokshin M, Li Y, Gaiddon C, Prives C. p53 and p73 display common and distinct requirements for sequence specific binding to DNA. Nucleic Acids Research. 35: 340-52. PMID 17170001 DOI: 10.1093/Nar/Gkl1047  0.773
2007 Mattia M, Gottifredi V, McKinney K, Prives C. p53-Dependent p21 mRNA elongation is impaired when DNA replication is stalled. Molecular and Cellular Biology. 27: 1309-20. PMID 17158927 DOI: 10.1128/Mcb.01520-06  0.86
2006 Peart MJ, Prives C. Mutant p53 gain of function: The NF-Y connection Cancer Cell. 10: 173-174. PMID 16959607 DOI: 10.1016/J.Ccr.2006.08.014  0.559
2006 Braithwaite AW, Prives CL. p53: More research and more questions Cell Death and Differentiation. 13: 877-880. PMID 16708075 DOI: 10.1038/Sj.Cdd.4401938  0.451
2006 Zupnick AE, Prives C. Mutational Analysis of the p53 Core Domain L1 Loop Journal of Biological Chemistry. 281: 20464-20473. PMID 16687402 DOI: 10.1074/Jbc.M603387200  0.857
2006 Ohkubo S, Tanaka T, Taya Y, Kitazato K, Prives C. Excess HDM2 impacts cell cycle and apoptosis and has a selective effect on p53-dependent transcription. Journal of Biological Chemistry. 281: 16943-16950. PMID 16624812 DOI: 10.1074/Jbc.M601388200  0.651
2006 Laptenko O, Prives C. Transcriptional regulation by p53: one protein, many possibilities. Cell Death & Differentiation. 13: 951-961. PMID 16575405 DOI: 10.1038/Sj.Cdd.4401916  0.593
2006 Poyurovsky MV, Prives C. Unleashing the power of p53: lessons from mice and men. Genes & Development. 20: 125-31. PMID 16418478 DOI: 10.1101/Gad.1397506  0.578
2006 Soria G, Podhajcer O, Prives C, Gottifredi V. P21Cip1/WAF1 downregulation is required for efficient PCNA ubiquitination after UV irradiation. Oncogene. 25: 2829-38. PMID 16407842 DOI: 10.1038/Sj.Onc.1209315  0.593
2006 Feng Z, Jin S, Zupnick A, Hoh J, de Stanchina E, Lowe S, Prives C, Levine AJ. p53 tumor suppressor protein regulates the levels of huntingtin gene expression. Oncogene. 25: 1-7. PMID 16278683 DOI: 10.1038/Sj.Onc.1209021  0.869
2006 Prives C, Tanaka T, Baptiste-Okoh N, Zupnick A. 232 INVITED Transcriptional regulation of apoptosis by the p53 tumor suppressor protein European Journal of Cancer Supplements. 4: 76. DOI: 10.1016/S1359-6349(06)70237-3  0.398
2005 Lokshin M, Tanaka T, Prives C. Transcriptional regulation by p53 and p73. Cold Spring Harbor Symposia On Quantitative Biology. 70: 121-8. PMID 16869745 DOI: 10.1101/Sqb.2005.70.046  0.8
2005 Desgranges ZP, Ahn J, Lazebnik MB, Ashworth T, Lee C, Pestell RC, Rosenberg N, Prives C, Roy AL. Inhibition of TFII-I-dependent cell cycle regulation by p53. Molecular and Cellular Biology. 25: 10940-52. PMID 16314517 DOI: 10.1128/Mcb.25.24.10940-10952.2005  0.467
2005 Okamoto K, Kashima K, Pereg Y, Ishida M, Yamazaki S, Nota A, Teunisse A, Migliorini D, Kitabayashi I, Marine J, Prives C, Shiloh Y, Jochemsen AG, Taya Y. DNA Damage-Induced Phosphorylation of MdmX at Serine 367 Activates p53 by Targeting MdmX for Mdm2-Dependent Degradation Molecular and Cellular Biology. 25: 9608-9620. PMID 16227609 DOI: 10.1128/Mcb.25.21.9608-9620.2005  0.595
2005 Prives C, Manfredi JJ. The continuing saga of p53--more sleepless nights ahead. Molecular Cell. 19: 719-21. PMID 16168367 DOI: 10.1016/J.Molcel.2005.08.024  0.572
2005 Gottifredi V, Prives C. The S phase checkpoint: when the crowd meets at the fork. Seminars in Cell & Developmental Biology. 16: 355-368. PMID 15840444 DOI: 10.1016/J.Semcdb.2005.02.011  0.344
2005 Vousden KH, Prives C. P53 and prognosis: new insights and further complexity. Cell. 120: 7-10. PMID 15652475 DOI: 10.1016/J.Cell.2004.12.027  0.473
2005 McKinney K, Prives C. Regulation of p53 DNA binding 25 Years of P53 Research. 27-51. DOI: 10.1007/978-1-4020-2922-6_2  0.839
2004 Urist M, Tanaka T, Poyurovsky MV, Prives C. p73 induction after DNA damage is regulated by checkpoint kinases Chk1 and Chk2. Genes & Development. 18: 3041-54. PMID 15601819 DOI: 10.1101/Gad.1221004  0.844
2004 Chuikov S, Kurash JK, Wilson JR, Xiao B, Justin N, Ivanov GS, McKinney K, Tempst P, Prives C, Gamblin SJ, Barlev NA, Reinberg D. Regulation of p53 activity through lysine methylation. Nature. 432: 353-60. PMID 15525938 DOI: 10.1038/Nature03117  0.852
2004 McKinney K, Mattia M, Gottifredi V, Prives C. p53 linear diffusion along DNA requires its C terminus. Molecular Cell. 16: 413-24. PMID 15525514 DOI: 10.1016/J.Molcel.2004.09.032  0.834
2004 Ahn J, Urist M, Prives C. The Chk2 protein kinase Dna Repair. 3: 1039-1047. PMID 15279791 DOI: 10.1016/J.Dnarep.2004.03.033  0.688
2004 Urist M, Prives C. The linchpin? Pin1 meets p73. Cancer Cell. 5: 515-517. PMID 15193253 DOI: 10.1016/J.Ccr.2004.06.001  0.791
2004 Baptiste N, Prives C. p53 in the cytoplasm: a question of overkill? Cell. 116: 487-489. PMID 14980216 DOI: 10.1016/S0092-8674(04)00164-3  0.856
2004 Puig P, Capodieci P, Drobnjak M, Verbel D, Prives C, Cordon-Cardo C, Di Como CJ. p73 Expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 9: 5642-51. PMID 14654547  0.301
2004 Gottifredi V, McKinney K, Poyurovsky MV, Prives C. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. The Journal of Biological Chemistry. 279: 5802-10. PMID 14597617 DOI: 10.1074/Jbc.M310373200  0.873
2003 Gonzalez S, Prives C, Cordon-Cardo C. p73alpha regulation by Chk1 in response to DNA damage. Molecular and Cellular Biology. 23: 8161-71. PMID 14585975 DOI: 10.1128/Mcb.23.22.8161-8171.2003  0.41
2003 Poyurovsky MV, Jacq X, Ma C, Karni-Schmidt O, Parker PJ, Chalfie M, Manley JL, Prives C. Nucleotide binding by the Mdm2 RING domain facilitates Arf-independent Mdm2 nucleolar localization. Molecular Cell. 12: 875-87. PMID 14580339 DOI: 10.1016/S1097-2765(03)00400-3  0.837
2003 Zhou J, Prives C. Replication of damaged DNA in vitro is blocked by p53. Nucleic Acids Research. 31: 3881-92. PMID 12853603 DOI: 10.1093/Nar/Gkg468  0.787
2003 Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP, Prives C. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. The Journal of Biological Chemistry. 278: 27421-31. PMID 12676926 DOI: 10.1074/Jbc.M300251200  0.748
2003 Ahn J, Urist M, Prives C. Questioning the role of checkpoint kinase 2 in the p53 DNA damage response. Journal of Biological Chemistry. 278: 20480-20489. PMID 12654916 DOI: 10.1074/Jbc.M213185200  0.783
2002 Haupt Y, Robles AI, Prives C, Rotter V. Deconstruction of p53 functions and regulation. Oncogene. 21: 8223-31. PMID 12447685 DOI: 10.1038/Sj.Onc.1206137  0.5
2002 Ahn J, Prives C. Checkpoint Kinase 2 (Chk2) Monomers or Dimers Phosphorylate Cdc25C after DNA Damage Regardless of Threonine 68 Phosphorylation Journal of Biological Chemistry. 277: 48418-48426. PMID 12386164 DOI: 10.1074/Jbc.M208321200  0.344
2002 McKinney K, Prives C. Efficient specific DNA binding by p53 requires both its central and C-terminal domains as revealed by studies with high-mobility group 1 protein. Molecular and Cellular Biology. 22: 6797-808. PMID 12215537 DOI: 10.1128/Mcb.22.19.6797-6808.2002  0.852
2002 Urist M, Prives C. p53 leans on its siblings. Cancer Cell. 1: 311-313. PMID 12086844 DOI: 10.1016/S1535-6108(02)00064-8  0.786
2002 Okamoto K, Li H, Jensen MR, Zhang T, Taya Y, Thorgeirsson SS, Prives C. Cyclin G Recruits PP2A to Dephosphorylate Mdm2 Molecular Cell. 9: 761-771. PMID 11983168 DOI: 10.1016/S1097-2765(02)00504-X  0.541
2002 Baptiste N, Friedlander P, Chen X, Prives C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene. 21: 9-21. PMID 11791172 DOI: 10.1038/Sj.Onc.1205015  0.868
2001 Prives C, Manley JL. Why is p53 acetylated? Cell. 107: 815-8. PMID 11779456 DOI: 10.1016/S0092-8674(01)00619-5  0.556
2001 Ahn J, Prives C. The C-terminus of p53: the more you learn the less you know. Nature Structural & Molecular Biology. 8: 730-732. PMID 11524665 DOI: 10.1038/Nsb0901-730  0.513
2001 Gottifredi V, Prives C. Getting p53 Out of the Nucleus Science. 292: 1851-1852. PMID 11397937 DOI: 10.1126/Science.1062238  0.512
2001 Zhang T, Prives C. Cyclin a-CDK phosphorylation regulates MDM2 protein interactions. Journal of Biological Chemistry. 276: 29702-29710. PMID 11359766 DOI: 10.1074/Jbc.M011326200  0.534
2001 Gottifredi V, Prives C. P53 and PML: new partners in tumor suppression Trends in Cell Biology. 11: 184-187. PMID 11316590 DOI: 10.1016/S0962-8924(01)01983-3  0.546
2001 Gaiddon C, Lokshin M, Ahn J, Zhang T, Prives C. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Molecular and Cellular Biology. 21: 1874-87. PMID 11238924 DOI: 10.1128/Mcb.21.5.1874-1887.2001  0.794
2001 Zhou J, Ahn J, Wilson SH, Prives C. A role for p53 in base excision repair Embo Journal. 20: 914-923. PMID 11179235 DOI: 10.1093/Emboj/20.4.914  0.794
2001 Gottifredi V, Karni-Schmidt O, Shieh SS, Prives C. p53 down-regulates CHK1 through p21 and the retinoblastoma protein. Molecular and Cellular Biology. 21: 1066-76. PMID 11158294 DOI: 10.1128/Mcb.21.4.1066-1076.2001  0.883
2001 Gottifredi V, Shieh S, Taya Y, Prives C. p53 accumulates but is functionally impaired when DNA synthesis is blocked. Proceedings of the National Academy of Sciences of the United States of America. 98: 1036-1041. DOI: 10.1073/Pnas.98.3.1036  0.602
2000 Gottifredi V, Shieh SY, Prives C. Regulation of p53 after different forms of stress and at different cell cycle stages. Cold Spring Harbor Symposia On Quantitative Biology. 65: 483-8. PMID 12760065 DOI: 10.1101/Sqb.2000.65.483  0.431
2000 Cain C, Miller S, Ahn J, Prives C. The N Terminus of p53 Regulates Its Dissociation from DNA Journal of Biological Chemistry. 275: 39944-39953. PMID 10993878 DOI: 10.1074/Jbc.M002509200  0.861
2000 Ferbeyre G, De Stanchina E, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence Genes and Development. 14: 2015-2027. PMID 10950866  0.345
2000 Bond GL, Prives C, Manley JL. Poly(A) polymerase phosphorylation is dependent on novel interactions with cyclins. Molecular and Cellular Biology. 20: 5310-20. PMID 10866687 DOI: 10.1128/Mcb.20.14.5310-5320.2000  0.354
2000 Ollmann M, Young LM, Di Como CJ, Karim F, Belvin M, Robertson S, Whittaker K, Demsky M, Fisher WW, Buchman A, Duyk G, Friedman L, Prives C, Kopczynski C. Drosophila p53 is a structural and functional homolog of the tumor suppressor p53. Cell. 101: 91-101. PMID 10778859 DOI: 10.1016/S0092-8674(00)80626-1  0.601
2000 Shieh S, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites Genes & Development. 14: 289-300. DOI: 10.1101/Gad.14.3.289  0.497
2000 Ferbeyre G, Stanchina Ed, Querido E, Baptiste N, Prives C, Lowe SW. PML is induced by oncogenic ras and promotes premature senescence Genes & Development. 14: 2015-2027. DOI: 10.1101/Gad.14.16.2015  0.823
1999 Cordon-Cardo C, Prives C. At the crossroads of inflammation and tumorigenesis. The Journal of Experimental Medicine. 190: 1367-70. PMID 10562311 DOI: 10.1084/Jem.190.10.1367  0.341
1999 Gaiddon C, Moorthy NC, Prives C. Ref-1 regulates the transactivation and pro-apoptotic functions of p53 in vivo. The Embo Journal. 18: 5609-21. PMID 10523305 DOI: 10.1093/Emboj/18.20.5609  0.66
1999 Okamoto K, Prives C. A role of cyclin G in the process of apoptosis. Oncogene. 18: 4606-4615. PMID 10467405 DOI: 10.1038/Sj.Onc.1202821  0.459
1999 White E, Prives C. DNA damage enables p73. Nature. 399: 734-5, 737. PMID 10391235 DOI: 10.1038/21539  0.505
1999 Prives C, Hall PA. The p53 pathway. The Journal of Pathology. 187: 112-26. PMID 10341712 DOI: 10.1002/(Sici)1096-9896(199901)187:1<112::Aid-Path250>3.0.Co;2-3  0.553
1999 Shieh SY, Taya Y, Prives C. DNA damage-inducible phosphorylation of p53 at N-terminal sites including a novel site, Ser20, requires tetramerization. The Embo Journal. 18: 1815-23. PMID 10202145 DOI: 10.1093/Emboj/18.7.1815  0.502
1999 Reynisdóttir I, Bhattacharyya S, Zhang D, Prives C. The retinoblastoma protein alters the phosphorylation state of polyomavirus large T antigen in murine cell extracts and inhibits polyomavirus origin DNA replication. Journal of Virology. 73: 3004-3013. PMID 10074150 DOI: 10.1128/Jvi.73.4.3004-3013.1999  0.364
1999 Jayaraman L, Prives C. Covalent and noncovalent modifiers of the p53 protein. Cellular and Molecular Life Sciences : Cmls. 55: 76-87. PMID 10065153 DOI: 10.1007/s000180050271  0.46
1999 Tibbetts RS, Brumbaugh KM, Williams JM, Sarkaria JN, Cliby WA, Shieh SY, Taya Y, Prives C, Abraham RT. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes & Development. 13: 152-7. PMID 9925639 DOI: 10.1101/Gad.13.2.152  0.491
1999 Como CJD, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Molecular and Cellular Biology. 19: 1438-1449. PMID 9891077 DOI: 10.1128/Mcb.19.2.1438  0.661
1999 Campagne MvL, Okamoto K, Prives C, Gill R. Developmental expression and co-localization of cyclin G1 and the B' subunits of protein phosphatase 2a in neurons. Molecular Brain Research. 64: 1-10. PMID 9889295 DOI: 10.1016/S0169-328X(98)00283-6  0.31
1999 Prikhod'ko GG, Wang Y, Freulich E, Prives C, Miller LK. Baculovirus p33 binds human p53 and enhances p53-mediated apoptosis. Journal of Virology. 73: 1227-34. PMID 9882325 DOI: 10.1128/Jvi.73.2.1227-1234.1999  0.608
1998 Vassilev A, Yamauchi J, Kotani T, Prives C, Avantaggiati ML, Qin J, Nakatani Y. The 400 kDa Subunit of the PCAF Histone Acetylase Complex Belongs to the ATM Superfamily Molecular Cell. 2: 869-875. PMID 9885574 DOI: 10.1016/S1097-2765(00)80301-9  0.46
1998 Prives C. Signaling To P53 : Breaking The Mdm2-P53 Circuit Cell. 95: 5-8. PMID 9778240 DOI: 10.1016/S0092-8674(00)81774-2  0.589
1998 Banin S, Moyal L, Shieh SY, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage Science. 281: 1674-1677. PMID 9733514 DOI: 10.1126/science.281.5383.1674  0.338
1998 de Stanchina E, McCurrach ME, Zindy F, Shieh SY, Ferbeyre G, Samuelson AV, Prives C, Roussel MF, Sherr CJ, Lowe SW. E1A signaling to p53 involves the p19(ARF) tumor suppressor. Genes & Development. 12: 2434-42. PMID 9694807 DOI: 10.1101/Gad.12.15.2434  0.631
1998 Como CJD, Prives C. Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. Oncogene. 16: 2527-2539. PMID 9627118 DOI: 10.1038/Sj.Onc.1202041  0.557
1998 Jayaraman L, Moorthy NC, Murthy KG, Manley JL, Bustin M, Prives C. High mobility group protein-1 (HMG-1) is a unique activator of p53. Genes & Development. 12: 462-72. PMID 9472015 DOI: 10.1101/Gad.12.4.462  0.581
1998 Colgan DF, Murthy KG, Zhao W, Prives C, Manley JL. Inhibition of poly(A) polymerase requires p34cdc2/cyclin B phosphorylation of multiple consensus and non-consensus sites. The Embo Journal. 17: 1053-62. PMID 9463383 DOI: 10.1093/Emboj/17.4.1053  0.35
1998 Niculescu AB, Chen X, Smeets M, Hengst L, Prives C, Reed SI. Effects of p21(Cip1/Waf1) at both the G1/S and the G2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and in preventing endoreduplication. Molecular and Cellular Biology. 18: 629-43. PMID 9418909 DOI: 10.1128/Mcb.18.1.629  0.552
1997 Ko LJ, Shieh SY, Chen X, Jayaraman L, Tamai K, Taya Y, Prives C, Pan ZQ. p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. Molecular and Cellular Biology. 17: 7220-9. PMID 9372954 DOI: 10.1128/Mcb.17.12.7220  0.572
1997 Shieh SY, Ikeda M, Taya Y, Prives C. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Cell. 91: 325-34. PMID 9363941 DOI: 10.1016/S0092-8674(00)80416-X  0.561
1997 Jayaraman L, Freulich E, Prives C. Functional dissection of p53 tumor suppressor protein Methods in Enzymology. 283: 245-256. PMID 9251024 DOI: 10.1016/S0076-6879(97)83020-0  0.632
1997 Miller SD, Moses K, Jayaraman L, Prives C. Complex formation between p53 and replication protein A inhibits the sequence-specific DNA binding of p53 and is regulated by single-stranded DNA. Molecular and Cellular Biology. 17: 2194-201. PMID 9121469 DOI: 10.1128/Mcb.17.4.2194  0.533
1997 Jayaraman L, Murthy KG, Zhu C, Curran T, Xanthoudakis S, Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. Genes & Development. 11: 558-70. PMID 9119221 DOI: 10.1101/Gad.11.5.558  0.631
1996 Oren M, Prives C. p53: Upstream, downstream and off stream. Review of the 8th p53 workshop (Dundee, July 5-9, 1996) Biochimica Et Biophysica Acta - Reviews On Cancer. 1288. PMID 9011182 DOI: 10.1016/S0304-419X(96)00030-3  0.533
1996 Farmer G, Friedlander P, Colgan J, Manley JL, Prives C. Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. Nucleic Acids Research. 24: 4281-8. PMID 8932384 DOI: 10.1093/Nar/24.21.4281  0.59
1996 Colgan DF, Murthy KG, Prives C, Manley JL. Cell-cycle related regulation of poly(A) polymerase by phosphorylation. Nature. 384: 282-5. PMID 8918882 DOI: 10.1038/384282A0  0.39
1996 Chen X, Ko LJ, Jayaraman L, Prives C. p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. Genes & Development. 10: 2438-51. PMID 8843196 DOI: 10.1101/Gad.10.19.2438  0.637
1996 Friedlander P, Legros Y, Soussi T, Prives C. Regulation of Mutant p53 Temperature-sensitive DNA Binding Journal of Biological Chemistry. 271: 25468-25478. PMID 8810317 DOI: 10.1074/Jbc.271.41.25468  0.564
1996 Friedlander P, Haupt Y, Prives C, Oren M. A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis Molecular and Cellular Biology. 16: 4961-4971. PMID 8756655 DOI: 10.1128/Mcb.16.9.4961  0.606
1996 Farmer G, Colgan J, Nakatani Y, Manley JL, Prives C. Functional interaction between p53, the TATA-binding protein (TBP), andTBP-associated factors in vivo. Molecular and Cellular Biology. 16: 4295-304. PMID 8754830 DOI: 10.1128/Mcb.16.8.4295  0.543
1996 Ko LJ, Prives C. p53: Puzzle and paradigm Genes and Development. 10: 1054-1072. PMID 8654922 DOI: 10.1101/GAD.10.9.1054  0.497
1995 Miller SD, Farmer G, Prives C. p53 Inhibits DNA replication in vitro in a DNA-binding-dependent manner Molecular and Cellular Biology. 15: 6554-6560. PMID 8524220 DOI: 10.1128/Mcb.15.12.6554  0.609
1995 Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. Journal of Virology. 69: 1851-9. PMID 7853526 DOI: 10.1128/JVI.69.3.1851-1859.1995  0.558
1995 Jayaraman J, Prives C. Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. Cell. 81: 1021-9. PMID 7600571 DOI: 10.1016/S0092-8674(05)80007-8  0.603
1995 Wang Y, Prives C. Increased and altered DNA binding of human p53 by S and G2/M but not Gl cyclin-dependent kinases Nature. 376: 88-91. PMID 7596441 DOI: 10.1038/376088A0  0.586
1994 Moses K, Prives C. A unique subpopulation of murine DNA polymerase α/primase specifically interacts with polyomavirus T antigen and stimulates DNA replication Molecular and Cellular Biology. 14: 2767-2776. PMID 8139575 DOI: 10.1128/Mcb.14.4.2767  0.332
1994 Prives C. How loops, β sheets, and α helices help us to understand p53 Cell. 78: 543-546. PMID 8069906 DOI: 10.1016/0092-8674(94)90519-3  0.336
1994 Prives C, Bargonetti J, Farmer G, Ferrari E, Friedlander P, Wang Y, Jayaraman L, Pavletich N, Hubscher U. DNA-binding properties of the p53 tumor suppressor protein Cold Spring Harbor Symposia On Quantitative Biology. 59: 207-213. PMID 7587071 DOI: 10.1101/Sqb.1994.059.01.025  0.511
1993 Prives C. Doing the right thing: feedback control and p53 Current Opinion in Cell Biology. 5: 214-218. PMID 8507493 DOI: 10.1016/0955-0674(93)90105-Y  0.609
1993 Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA Proceedings of the National Academy of Sciences of the United States of America. 90: 3319-3323. PMID 8475074 DOI: 10.1073/Pnas.90.8.3319  0.592
1993 Wang EH, Bhattacharyya S, Prives C. The replication functions of polyomavirus large tumor antigen are regulated by phosphorylation. Journal of Virology. 67: 6788-6796. PMID 8411381 DOI: 10.1128/Jvi.67.11.6788-6796.1993  0.333
1993 Chen X, Farmer G, Zhu H, Prywes R, Prives C. Cooperative DNA binding of p53 with TFIID (TBP): a possible mechanism for transcriptional activation. Genes & Development. 7: 1837-49. PMID 8405994 DOI: 10.1101/Gad.7.10.1837  0.611
1993 Lorimer HE, Reynisdöttir I, Ness S, Prives C. Unusual Properties of a Replication-Defective Mutant SV40 Large T Antigen Virology. 192: 402-414. PMID 8380658 DOI: 10.1006/Viro.1993.1055  0.301
1993 Bargonetti J, Manfredi JJ, Chen X, Marshak DR, Prives C. A proteolytic fragment from the central region of p53 has marked sequence-specific DNA-binding activity when generated from wild-type but not from oncogenic mutant p53 protein Genes and Development. 7: 2565-2574. PMID 8276239 DOI: 10.1101/Gad.7.12B.2565  0.554
1993 Prives C, Manfredi JJ. The p53 tumor suppressor protein: meeting review. Genes & Development. 7: 529-534. PMID 8096197 DOI: 10.1101/Gad.7.4.529  0.454
1993 Friedman PN, Wang EH, Meerovitch K, Sonenberg N, Prives C. Murine p53 inhibits the function but not the formation of SV40 T antigen hexamers and stimulates T antigen RNA helicase activity. Chromosoma. 102: S60-6. PMID 1337881 DOI: 10.1007/Bf02451787  0.447
1992 Zambetti GP, Bargonetti J, Walker K, Prives C, Levine AJ. Wild-type p53 mediates positive regulation of gene expression through a specific DNA sequence element Genes and Development. 6: 1143-1152. PMID 1628822 DOI: 10.1101/Gad.6.7.1143  0.576
1992 Farmer G, Bargonetti J, Zhu H, Friedman P, Prywes R, Prives C. Wild-type p53 activates transcription in vitro. Nature. 358: 83-6. PMID 1614538 DOI: 10.1038/358083A0  0.597
1992 Bargonetti J, Reynisdottir I, Friedman PN, Prives C. Site-specific binding of wild-type p53 to cellular DNA is inhibited by SV40 T antigen and mutant p53 Genes and Development. 6: 1886-1898. PMID 1398068 DOI: 10.1101/Gad.6.10.1886  0.566
1991 Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type, but not mutant, human p53 proteins inhibit the replication activities of simian virus 40 large tumor antigen. Proceedings of the National Academy of Sciences of the United States of America. 87: 9275-9. PMID 2174557 DOI: 10.1073/Pnas.87.23.9275  0.588
1991 Kern SE, Kinzler KW, Bruskin A, Jarosz D, Friedman P, Prives C, Vogelstein B. Identification of p53 as a sequence-specific DNA-binding protein. Science (New York, N.Y.). 252: 1708-11. PMID 2047879 DOI: 10.1126/Science.2047879  0.427
1991 Lorimer HE, Wang EH, Prives C. The DNA-binding properties of polyomavirus large T antigen are altered by ATP and other nucleotides Journal of Virology. 65: 687-699. PMID 1846192 DOI: 10.1128/Jvi.65.2.687-699.1991  0.357
1991 Prives C, Bargonetti J, Friedman PN, Manfredi JJ, Wang EH. Functional consequences of the interactions of the p53 tumor suppressor protein and SV40 large tumor antigen Cold Spring Harbor Symposia On Quantitative Biology. 56: 227-235. PMID 1668081 DOI: 10.1101/Sqb.1991.056.01.028  0.39
1991 Bargonetti J, Friedman PN, Kern SE, Vogelstein B, Prives C. Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication Cell. 65: 1083-1091. PMID 1646078 DOI: 10.1016/0092-8674(91)90560-L  0.57
1990 Reynisdóttir I, O'Reilly DR, Miller LK, Prives C. Thermally inactivated simian virus 40 tsA58 mutant T antigen cannot initiate viral DNA replication in vitro. Journal of Virology. 64: 6234-6245. PMID 2173789 DOI: 10.1128/Jvi.64.12.6234-6245.1990  0.333
1990 Bischoff JR, Friedman PN, Marshak DR, Prives C, Beach D. Human p53 is phosphorylated by p60-cdc2 and cyclin B-cdc2. Proceedings of the National Academy of Sciences of the United States of America. 87: 4766-70. PMID 2141171 DOI: 10.1073/PNAS.87.12.4766  0.447
1989 Pan Z, Prives C. U2 snRNA sequences that bind U2-specific proteins are dispensable for the function of U2 snRNP in splicing. Genes & Development. 3: 1887-1898. PMID 2559872 DOI: 10.1101/Gad.3.12A.1887  0.304
1989 Wang EH, Friedman PN, Prives C. The murine p53 protein blocks replication of SV40 DNA in vitro by inhibiting the initiation functions of SV40 large T antigen Cell. 57: 379-392. PMID 2541911 DOI: 10.1016/0092-8674(89)90913-6  0.551
1988 Auborn KJ, Markowitz RB, Wang E, Yu YT, Prives C. Simian virus 40 (SV40) T antigen binds specifically to double-stranded DNA but not to single-stranded DNA or DNA/RNA hybrids containing the SV40 regulatory sequences. Journal of Virology. 62: 2204-8. PMID 3367427 DOI: 10.1128/Jvi.62.6.2204-2208.1988  0.347
1987 Michaeli T, Prives C. pBR322 DNA inhibits simian virus 40 gene expression in Xenopus laevis oocytes. Nucleic Acids Research. 15: 1579-94. PMID 3029720 DOI: 10.1093/Nar/15.4.1579  0.368
1987 Prives C, Murakami Y, Kern FG, Folk W, Basilico C, Hurwitz J. DNA sequence requirements for replication of polyomavirus DNA in vivo and in vitro Molecular and Cellular Biology. 7: 3694-3704. PMID 2824994 DOI: 10.1128/Mcb.7.10.3694  0.383
1986 Bolen JB, Cary K, Scheller A, Basilico C, Israel MA, Prives C. A subclass of polyomavirus middle tumor antigen binds to DNA cellulose Journal of Virology. 58: 157-164. PMID 3005644 DOI: 10.1128/Jvi.58.1.157-164.1986  0.331
1984 Prives C, Covey L, Scheller A, Gluzman Y. DNA-binding properties of simian virus 40 T-antigen mutants defective in viral DNA replication. Molecular and Cellular Biology. 3: 1958-66. PMID 6318076 DOI: 10.1128/Mcb.3.11.1958  0.317
1984 Fradin A, Jove R, Hemenway C, Keiser HD, Manley JL, Prives C. Splicing pathways of SV40 mRNAs in X. laevis oocytes differ in their requirements for snRNPs. Cell. 37: 927-36. PMID 6086149 DOI: 10.1016/0092-8674(84)90427-6  0.303
1984 Prives C. Advances in Viral Oncology. Volume 2: The Transformation-Associated Cellular p53 Protein.George Klein The Quarterly Review of Biology. 59: 62-63. DOI: 10.1086/413688  0.306
1983 May E, Lasne C, Prives C, Borde J, May P. Study of the Functional Activities Concomitantly Retained by the 115,000 Mr Super T Antigen, an Evolutionary Variant of Simian Virus 40 Large T Antigen Expressed in Transformed Rat Cells Journal of Virology. 45: 901-913. PMID 6300461 DOI: 10.1128/Jvi.45.3.901-913.1983  0.377
1982 Fradin A, Manley JL, Prives CL. Methylation of simian virus 40 Hpa II site affects late, but not early, viral gene expression. Proceedings of the National Academy of Sciences of the United States of America. 79: 5142-6. PMID 6291026 DOI: 10.1073/Pnas.79.17.5142  0.335
1982 Scheller A, Covey L, Barnet B, Prives C. A small subclass of SV40 T antigen binds to the viral origin of replication. Cell. 29: 375-83. PMID 6288256 DOI: 10.1016/0092-8674(82)90154-4  0.318
1982 Prives C, Barnet B, Scheller A, Khoury G, Jay G. Discrete regions of simian virus 40 large T antigen are required for nonspecific and viral origin-specific DNA binding. Journal of Virology. 43: 73-82. PMID 6287017 DOI: 10.1128/Jvi.43.1.73-82.1982  0.311
1982 Gidoni D, Scheller A, Barnet B, Hantzopoulos P, Oren M, Prives C. Different forms of simian virus 40 large tumor antigen varying in their affinities for DNA. Journal of Virology. 42: 456-466. DOI: 10.1128/Jvi.42.2.456-466.1982  0.303
1981 Prives C, Beck Y, Gidoni D, Oren M, Shure H. DNA binding and sedimentation properties of SV40 T antigens synthesized in vivo and in vitro. Cold Spring Harbor Symposia On Quantitative Biology. 123-30. PMID 6253125 DOI: 10.1101/Sqb.1980.044.01.014  0.315
1980 Prives C, Beck Y, Shure H. DNA binding properties of simian virus 40 T-antigens synthesized in vivo and in vitro. Journal of Virology. 33: 689-696. PMID 6251241 DOI: 10.1128/Jvi.33.2.689-696.1980  0.312
1980 Oren M, Winocour E, Prives C. Differential affinities of simian virus 40 large tumor antigen for DNA. Proceedings of the National Academy of Sciences of the United States of America. 77: 220-4. PMID 6244545 DOI: 10.1073/Pnas.77.1.220  0.33
1969 Prives C, Quastel JH. Effect of cerebral stimulation on biosynthesis of nucleotides and RNA in brain slices in vitro Bba Section Nucleic Acids and Protein Synthesis. 182: 285-294. PMID 5795481 DOI: 10.1016/0005-2787(69)90179-8  0.397
1969 Prives C, Quastel JH. Effects of cerebral stimulation on the biosynthesis in vitro of nucleotides and RNA in brain [15] Nature. 221: 1053. DOI: 10.1038/2211053a0  0.388
Show low-probability matches.